The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
Ikena, Senti and others look to clinical presentations at AACR.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.